Table 1 Demographic and Clinical Characteristics at Baseline
Characteristics | Enrolled patients (N = 879) | |
|---|---|---|
Demographics | Age, years | 54.4 ± 11.5 |
Female, no (%) | 692 (78.7) | |
White, no (%) | 820 (93.3) | |
Disease duration, years | 12.5 ± 9.7 | |
RF > 20 IU/mL, no (%) | 661 (75.2) | |
ACR core set | Tender joint count (0-68 scale) | 14.9 ± 7.1 |
Swollen joint count (0-66 scale) | 13.2 ± 5.2 | |
Patient's assessment of pain, mm (0-100 mm VAS)a | 66.2 ± 22.3 | |
Patient's global assessment of disease activity, mm (0-100 mm VAS)b | 65.1 ± 22.7 | |
Physician's global assessment of disease activity, mm (0-100 mm VAS)b | 63.7 ± 17.6 | |
HAQ-DI score (0-3 scale)c | 1.5 ± 0.6 | |
DAS28 Score | 6.1 ± 1.2 | |
Acute phase reactants | ESR (mm/hr) (normal value < 20 mm/h for men, < 30 mm/h for women) | 30.3 ± 23.8 |
CRP (mg/L) (normal value < 10 mg/L) | 24.0 ± 30.8 | |
Quality of life | HUI2 score | 0.59 ± 0.22 |
HUI3 score | 0.38 ± 0.29 | |
DMARD therapy | Receiving adalimumab + 0 DMARD, no. (%) | 135 (15.4) |
Receiving adalimumab + 1 DMARD, no. (%) | 371 (42.2) | |
Receiving adalimumab + 2 DMARDs, no. (%) | 284 (32.3) | |
Receiving adalimumab + ≥ 3 DMARDs, no. (%) | 89 (10.1) | |
Receiving methotrexate, no (%) | 549 (62.5) | |
Receiving leflunomide, no. (%) | 248 (28.2) | |
Receiving sulfasalazine, no. (%) | 104 (11.8) | |
Receiving hydroxychloroquine, no. (%) | 248 (28.2) | |
Receiving prednisone, no. (%) | 381 (43.3) | |
Prednisone ≤ 5 mg, no. (%) | 158 (18) | |
Prednisone > 5 mg, no. (%) | 223 (25.3) | |
Patients that received prior BDMARD therapy no. (%) | 242 (27.5) | |
Patients that received etanercept no. (%) | 131 (54.1) | |
Patients that received infliximab no. (%) | 65 (26.9) | |
Patients that received other BDMARD no. (%) | 46 (19) | |